Predicting impact of tirzepatide in patients with OSA, obesity

ORLANDO — Patients with obstructive sleep apnea and obesity who had strong- vs. moderate-response endotype characteristics had more improvement in obstructive sleep apnea severity with tirzepatide, according to data presented here.
These findings were presented at the American Thoracic Society International Conference.
“We are excited about these findings because they offer the chance to now be able to share with patients: ‘You have the characteristics that place you in a group of patients who respond remarkably to tirzepatide weight loss therapy.’ Or, by contrast, ‘You have characteristics

